CN109125355A - The grand antiplatelet of heart arteries and veins and antithrombotic pharmacology action - Google Patents
The grand antiplatelet of heart arteries and veins and antithrombotic pharmacology action Download PDFInfo
- Publication number
- CN109125355A CN109125355A CN201810875028.8A CN201810875028A CN109125355A CN 109125355 A CN109125355 A CN 109125355A CN 201810875028 A CN201810875028 A CN 201810875028A CN 109125355 A CN109125355 A CN 109125355A
- Authority
- CN
- China
- Prior art keywords
- grand
- veins
- heart arteries
- antiplatelet
- antithrombotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The grand antiplatelet of heart arteries and veins and antithrombotic pharmacology action.The present invention relates to the grand applications in terms of antiplatelet and antithrombotic pharmacology of heart arteries and veins, belong to pharmaceutical chemistry, area of pharmacology.The invention discloses the pharmacological actions of the grand antiplatelet of heart arteries and veins and antithrombotic, it is studied from molecule, whole animal model dual-layer face, its effect to platelet aggregation activity is measured by external people's blood platelet aggregation test, its effect to internal thrombotic diseases is studied by chmice acute pulmonary embolism model.It is demonstrated experimentally that heart arteries and veins is grand to have apparent inhibiting effect to platelet function and thrombotic diseases, experimental basis is provided for the research later in terms of antiplatelet and antithrombotic.
Description
Technical field
The present invention relates to the grand applications in terms of antiplatelet and antithrombotic pharmacology of heart arteries and veins, belong to pharmaceutical chemistry, medicine
Field of science.
Technical background
Cardiovascular and cerebrovascular disease mainly includes ischemic heart disease, acute myocardial infarction AMI, pulmonary infarction, cerebral apoplexy, cerebral infarction etc.
Common disease, great threat human health and life are China resident first place causes of the death[1].And generation, the development of cardiovascular and cerebrovascular disease
Mainly platelet activation, adherency, aggregation are until a series of cascade reaction of thrombosis[2, 3].Therefore, inhibit blood platelet function
Energy and thrombosis are most important for the prevention and treatment of cardiovascular and cerebrovascular disease.
Grand heart arteries and veins is a kind of clinical medicine insect extract for matters of containing biological activities made of main component, belongs to state
Family's two kind new medicine of Chinese medicine (national drug standard Z20060443, Chinese Patent Application No. 94118839.6).Grand heart arteries and veins is by cockroach, beauty
The extracts such as the big Lian in continent are made and purified treated medicinal extract, the medicinal extract are mainly made of compound nucleosides and viscous propylhomoserin, can also
Contain a small amount of free amino acid, neutral sugar, viscous sugar[4].Heart arteries and veins is grand to have wide therapeutic effect to cardiovascular disease, and
Pass through acute toxicity test and long term toxicity test[4].Research, which finds that heart arteries and veins is grand, mainly to be had enhancing myocardial contractive power, boosts, changes
Kind microcirculation, antiatherosclerosis increase coronary flow, and excitement breathing increases the pharmacology such as renal hemodynamic and diuresis and makees
With[5, 6].It is clinically commonly used to treatment acute and chronic heart failure, shock, myocardial ischemia disease at present, can obviously improve micro-
Circulation, achieves good clinical efficacy, but the influence to platelet function and thrombotic diseases yet there are no relevant report.
Summary of the invention
The object of the present invention is to provide a kind of grand Chinese medicines of heart arteries and veins to be used to prepare answering in antiplatelet and anti-thrombotic agents
With.
The grand Chinese medicine of heart arteries and veins can be used for preparing the preparation of antiplatelet and antithrombotic.
The grand pharmacological action with antiplatelet and antithrombotic of the heart arteries and veins, passes through external people's blood platelet aggregation test
Its effect to platelet aggregation activity is measured, it is studied by chmice acute pulmonary embolism model to mouse thrombotic diseases
Effect.It is demonstrated experimentally that heart arteries and veins is grand to have apparent inhibiting effect to platelet function and mouse thrombotic diseases.Involved by the present invention
And the grand pharmacological action of new heart arteries and veins, so far there is not yet relevant report.
It is with physiological saline solution medicinal extract that heart arteries and veins of the present invention is grand, and concentration is indicated with m/v.
In above-mentioned external people's blood platelet aggregation test, following various concentration 0mg/ml, 0.1mg/ml, 1 mg/ are measured
The grand influence to people's blood platelet aggregation of heart arteries and veins of ml, 10 mg/ml.
In above-mentioned chmice acute pulmonary embolism model experiment, administration concentration is 0mg/kg, 10mg/kg, 20mg/kg respectively,
And clinically conventional antiplatelet drug aspirin 50mg/kg, lung row H & E left to each group mouse are dyed, light is under the microscope
In lung tissue in capilary thrombus form, distribution, the morphological change of interstitial lung and essence while measuring depositing for each group mouse
Live time, to assess the grand influence to thrombosis of heart arteries and veins.
The present invention is studied from molecule, whole animal model dual-layer face, it is found that heart arteries and veins is grand can inhibit collagen
(Collagen), fibrin ferment (Thrombin), arachidonic acid (Arachidonic acid, AA), adenosine diphosphate (ADP) (ADP)
Platelet aggregation caused by equal agonists, and can inhibit the formation of chmice acute lung thrombus, extend the life span of mouse.
The grand another biological characteristics performance of heart arteries and veins provided by the present invention predicts its many application.
The present invention can be related to for thrombotic diseases: assessment platelet aggregation evaluates Antiplatelet therapy (Ru Asi
Woods, clopidogrel, ticagrelor etc.) the now or in the future validity for the treatment of；Meanwhile because it inhibits platelet aggregation,
It can be used for curing thrombus.
The present invention can be used as the purposes of cicatrization agent or dermatology emulsion: certain wound scars are formed or Cutaneous disease
The healing of disease needs migration on the spot, adherency, aggregation and the activation of blood platelet.
Detailed description of the invention
Fig. 1 is grand (0mg/ml, 0.1mg/ml, 1 mg/ml, 10 mg/ml) through optics turbidimetry detection various concentration heart arteries and veins
The curve of platelet aggregation figure that the platelet aggregation of collagen, ADP, arachidonic acid, thrombin induction is influenced.Wash blood platelet
With the heart arteries and veins of various concentration is grand is incubated at 37 DEG C after ten minutes, collagen, fibrin ferment, arachidonic acid, the induction such as ADP is added
Agent, and record curve of platelet aggregation (mean, n >=3).
Fig. 2 is grand (0mg/ml, 0.1mg/ml, 1 mg/ml, 10 mg/ml) through optics turbidimetry detection various concentration heart arteries and veins
The bar graph that the platelet aggregation of collagen, ADP, arachidonic acid, thrombin induction is influenced.[mean ± standard error, n >=3；*
(P < 0.05), * * (P < 0.01)].
Fig. 3 be various concentration heart arteries and veins grand (0mg/kg, 10mg/kg, 20mg/kg) and clinically conventional antiplatelet drug Ah
The influence of time-to-live after the chmice acute lung thrombus that department woods (50mg/kg) induces collagen and adrenalin.(abscissa is
Grouping, ordinate is the time-to-live: s)
Fig. 4 conventional antiplatelet drug aspirin for various concentration heart arteries and veins grand (10mg/kg, 20mg/kg) and clinically
The left lung tissue row H & E dyeing of mouse after the chmice acute lung thrombus that (50mg/kg) induces collagen and adrenalin, times magnification
Number: 10X4.
Specific embodiment
1. washing the preparation of blood platelet and the grand solution of heart arteries and veins
It washs the preparation of blood platelet: taking healthy volunteer's ulnar vein blood in 3.8% sodium citrate (1:9) anticoagulant tube, Tyrode
Buffer isometric (1:1) dilution, while the final concentration of 50ng/ml of PGE1(is added)；200 × g is centrifuged 15min, draws upper layer
The final concentration of 50ng/ml of PGE1(is added in liquid rich in blood platelet), 1000 × g is centrifuged 10min, discards supernatant liquid, obtains
Appropriate Tyrode Buffer is added in Platelet Concentrate agglomerate, and is separately added into the final concentration of 50ng/ml of PGE1() and final concentration
1mM EDTA, pasteur pipet are softly blown and beaten, and blood platelet is resuspended；1000 × g is centrifuged 10min, discards supernatant liquid, obtains blood platelet group
Appropriate Tyrode Buffer is added in block, soft to blow and beat, and blood platelet is resuspended；Platelet count is measured with haemocyte automatic analyzer
Mesh, it is 3 × 10 that Tyrode Buffer, which adjusts number of platelets,8A/ml, room temperature storage are spare.
The configuration of the grand solution of heart arteries and veins: the heart arteries and veins that physiological saline is configured to 100 mg/ml is dissolved under the grand medicinal extract room temperature of coring arteries and veins
Grand liquid, room temperature storage are spare.
2. the measurement of people's blood platelet aggregation
(1) platelet aggregation is measured using turbidimetry principle, is carried out on Chrono-Log company binary channels platelet aggregation instrument,
To 37 DEG C, recorder chart drive speed is set as 1cm/ minutes preheating platelet aggregation instrument first.400ul blood is added in opacity tube
Platelet suspension and stirrer, after the grand incubation of various concentration (0.1mg/kg, 1mg/kg, 10mg/kg) heart arteries and veins being added 10 minutes, with
Tyrode Buffer is reference, and (1200rpm) traces baseline under 37 DEG C of constant temperature constant speed magnetic agitations, after baseline stability, is added
Different agonists (fibrin ferment, arachidonic acid, collagen, adenosine diphosphate (ADP) etc.) observe and record aggregation curvilinear motion.At least repeat
Three times, it is averaged.Curve of platelet aggregation figure (Fig. 1) is recorded according to platelet aggregation rate and draws corresponding bar graph (figure
2).Meanwhile being calculated by the following formula L-Arginine: [(X-Y)/X] * 100%.X represents each agonist induction
Blood platelet average aggregate rate；Y represents the blood platelet average aggregate rate of grand+each agonist induction of various concentration heart arteries and veins.
(2) experimental data is handled with 21.0 statistical software of SPSS.As a result it is indicated with mean ± standard error.Between multiple groups
More advanced row homogeneity test of variance, the neat person of variance are compared used LSD two-by-two with one-way analysis of variance (one-way ANOVA)
(least-significant difference, i.e. least significant difference method) is examined；Row Tamhane ' the s if heterogeneity of variance
T2 is examined, and compares examined using t two-by-two.Think that difference has statistical significance in p < 0.05 item.
From experimental result as can be seen that in above-mentioned effective dosage ranges, heart arteries and veins of the present invention is grand to fibrin ferment, flower
People's blood platelet aggregation that raw tetraenoic acid (AA), collagen (Collagen), adenosine diphosphate (ADP) (ADP) induce has significant inhibition to make
With presentation dose-dependence (table 1A and table 1B, Fig. 1, Fig. 2).
Table 1A
Table 1B
From table 1A and table 1B it is found that heart arteries and veins of the present invention is grand in above-mentioned effective dosage ranges, to arachidonic acid (AA),
People's blood platelet aggregation that fibrin ferment, collagen (Collagen), adenosine diphosphate (ADP) (ADP) induce has significant inhibiting effect, is in
Existing dose-dependence.
3. the effect of the grand chmice acute lung thrombus to collagen and adrenalin induction of heart arteries and veins
Experimental animal is kunming mice 50, and weight 20-30g is provided, perhaps by Hunan SJA Laboratory Animal Co. , Ltd
Can the number of card: the Yunnan SYXK() 2013-0004.
1) mouse is weighed, and is recorded and is grouped, this experiment is divided into 5 groups: the grand 10mg/kg group of blank group, model group, heart arteries and veins, the heart
The grand 20mg/kg group of arteries and veins and aspirin 50mg/kg group, every group 10；
2) configuration collagen (1.0mg/kg) and adrenaline (100ug/kg) Mixtard makees model inducer;
3) mouse is administered by group tail vein injection, and blank control group, model group give physiological saline, and positive controls are given
50mg/kg aspirin, medication group give heart arteries and veins grand 10mg/kg, 20mg/kg respectively;
4) after 30min being administered, collagen and adrenalin mixed liquor tail vein injection modeling is used;
5) time-to-live of mice behavior change and each group mouse in modeling 5min is recorded;
6) the left lung of each group mouse is taken out, is fixed using 4% paraformaldehyde solution;
7) be sliced after fixed, H & E dyeing, in light microscopic observation lung tissue in capilary thrombus form, distribution, interstitial lung and
The morphological change of essence.
Experimental data is handled with 21.0 statistical software of SPSS.As a result it is indicated with mean ± standard error.It is more advanced between multiple groups
Row homogeneity test of variance, the neat person of variance are compared used LSD(least- two-by-two with one-way analysis of variance (one-way ANOVA)
Significant difference, i.e. least significant difference method) it examines；Row Tamhane ' s T2 is examined if heterogeneity of variance
It tests, compares examined using t two-by-two.Think that difference has statistical significance in p < 0.05 item.
Experimental result is shown: compared with model group (152.40 ± 2.31s), the grand 10mg/kg group of heart arteries and veins (306.10 ±
17.51s, p < 0.05) the grand 20mg/kg group of He Xinmai (352.70 ± 10.53s, p < 0.05) and 50mg/kg aspirin group
(367.10 ± 14.39s, p < 0.05) can extend mouse diing time, and have significant difference (Fig. 3)；Wherein, 50mg/
Kg aspirin group can be such that mouse death rate reduces with the grand 20mg/kg group of heart arteries and veins, and have no obvious statistical difference (p >
0.05) (Fig. 3) illustrates that the grand 20mg/kg group of heart arteries and veins inhibits the effect of internal thrombosis suitable with 50mg/kg aspirin group
(table 2).
Table 2
As can be seen from Table 2, the grand chmice acute lung bolt for delaying collagen and adrenalin mixed liquor to induce of heart arteries and veins provided by the invention
Death time after plug, and the grand 20mg/kg group of heart arteries and veins and clinically conventional antiplatelet drug 50mg/kg aspirin group is anti-
Thrombus function and effect are suitable.
Showed by immune group result: blank group is without thrombosis (Fig. 4 A), obvious (such as Fig. 4 B arrow of model group thrombosis
It is shown), and aspirin group and the grand high dose group of heart arteries and veins (20mg/kg) are substantially reduced thrombosis (such as Fig. 4 E, 4D arrow institute
Show), visible microthrombus is formed in the grand low dose group of heart arteries and veins (10mg/kg), but reduces (such as Fig. 4 C arrow compared with model group thrombosis
It is shown).Therefore it draws a conclusion, the formation of the grand internal thrombus to collagen and adrenalin induction of heart arteries and veins is inhibited.
Bibliography
[1] Chen Weiwei, Gao Runlin, Liu Lisheng, Zhu Manlu, Wang Wen, Wang Yongjun, et al. " Chinese cardiovascular disease report
2017 " summary [J] China recycles magazine .2018, (01): 1-8..
[2]George JN.Platelets[J].Lancet (London, England).2000,355(9214):
1531-9。
[3]Jurk K, Kehrel BE.[Pathophysiology and biochemistry of platelets]
[J].Der Internist.2010,51(9):1086, 8-92, 94。
[4] Japanese plum nanmu, Hu Zhong Xinmailong medicinal extract and the Yunnan Xinmailong pharmaceutical formulation [P]: CN1124141,1996-
06-12。
[5] Summary of Research Progress [J] the R&D of modern TCM of Hu Changjun Xinmailong injection and .2013 is practiced, (04):
84-5。
[6] pharmacological action of Tang Xiao letter Xinmailong injection and treatment heart failure clinical progress [J] China new drug
Magazine .2008, (06): 461-4.
Claims (5)
1. a kind of grand Chinese medicine of heart arteries and veins is in the application being used to prepare in antiplatelet and anti-thrombotic agents.
2. the grand Chinese medicine of heart arteries and veins according to claim 1 is in the application being used to prepare in antiplatelet and anti-thrombotic agents,
It is characterized in that: the work that the application of the preparation measures it to platelet aggregation activity by external people's blood platelet aggregation test
With；Its effect to mouse thrombotic diseases is studied by chmice acute pulmonary embolism model.
3. the grand Chinese medicine of heart arteries and veins according to claim 2 is in the application being used to prepare in antiplatelet and anti-thrombotic agents,
Be characterized in that: with physiological saline solution in the form of medicinal extract, concentration is indicated with m/v.
4. the grand Chinese medicine of heart arteries and veins according to claim 2 is in the application being used to prepare in antiplatelet and anti-thrombotic agents,
It is characterized in that: it is grand to people's blood blood platelet to measure following various concentration 0mg/ml, 0.1mg/ml, 1 mg/ml, the heart arteries and veins of 10 mg/ml
The influence of aggregation capability.
5. the grand Chinese medicine of heart arteries and veins according to claim 2 is in the application being used to prepare in antiplatelet and anti-thrombotic agents,
Be characterized in that: administration concentration is 0mg/kg, 10mg/kg, 20mg/kg respectively in chmice acute pulmonary embolism model, and clinically
Conventional antiplatelet drug aspirin 50mg/kg, lung row H & E left to each group mouse is dyed, micro- in light microscopic observation lung tissue
The form of Intravascular Thrombus, distribution, the morphological change of interstitial lung and essence, while the time-to-live of each group mouse is measured, come
Assess the grand influence to thrombosis of heart arteries and veins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810875028.8A CN109125355B (en) | 2018-08-03 | 2018-08-03 | Psychopharmacology application of Xinmailong for anti-platelet and anti-thrombus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810875028.8A CN109125355B (en) | 2018-08-03 | 2018-08-03 | Psychopharmacology application of Xinmailong for anti-platelet and anti-thrombus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109125355A true CN109125355A (en) | 2019-01-04 |
| CN109125355B CN109125355B (en) | 2022-07-08 |
Family
ID=64791433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810875028.8A Active CN109125355B (en) | 2018-08-03 | 2018-08-03 | Psychopharmacology application of Xinmailong for anti-platelet and anti-thrombus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109125355B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0383533A1 (en) * | 1989-02-15 | 1990-08-22 | Eimei Company Ltd | Therapeutic medicament for thrombosis and method for preparation thereof |
| WO1993005150A1 (en) * | 1991-09-05 | 1993-03-18 | Schering Aktiengesellschaft | Collagen-induced platelet aggregation inhibitor |
| CN1124141A (en) * | 1994-12-09 | 1996-06-12 | 大理医学院 | Xinmailong extract and Xinmailong medical preparation for curing angiocardiopath |
| CN102391360A (en) * | 2011-11-02 | 2012-03-28 | 东南大学 | Small peptide capable of resisting thrombosis and platelet aggregation |
| CN103113456A (en) * | 2013-03-05 | 2013-05-22 | 中国药科大学 | Stiff silkworm polypeptide with antiplatelet aggregation activity as well as preparation method and application of stiff silkworm polypeptide |
| CN106109564A (en) * | 2016-07-04 | 2016-11-16 | 济南星懿医药技术有限公司 | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof |
| CN106370738A (en) * | 2016-08-18 | 2017-02-01 | 四川好医生攀西药业有限责任公司 | Periplaneta americana medicinal material fingerprint quality determination method |
| CN107753535A (en) * | 2017-02-21 | 2018-03-06 | 四川好医生攀西药业有限责任公司 | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease and its application |
-
2018
- 2018-08-03 CN CN201810875028.8A patent/CN109125355B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0383533A1 (en) * | 1989-02-15 | 1990-08-22 | Eimei Company Ltd | Therapeutic medicament for thrombosis and method for preparation thereof |
| WO1993005150A1 (en) * | 1991-09-05 | 1993-03-18 | Schering Aktiengesellschaft | Collagen-induced platelet aggregation inhibitor |
| CN1124141A (en) * | 1994-12-09 | 1996-06-12 | 大理医学院 | Xinmailong extract and Xinmailong medical preparation for curing angiocardiopath |
| CN102391360A (en) * | 2011-11-02 | 2012-03-28 | 东南大学 | Small peptide capable of resisting thrombosis and platelet aggregation |
| CN103113456A (en) * | 2013-03-05 | 2013-05-22 | 中国药科大学 | Stiff silkworm polypeptide with antiplatelet aggregation activity as well as preparation method and application of stiff silkworm polypeptide |
| CN106109564A (en) * | 2016-07-04 | 2016-11-16 | 济南星懿医药技术有限公司 | Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof |
| CN106370738A (en) * | 2016-08-18 | 2017-02-01 | 四川好医生攀西药业有限责任公司 | Periplaneta americana medicinal material fingerprint quality determination method |
| CN107753535A (en) * | 2017-02-21 | 2018-03-06 | 四川好医生攀西药业有限责任公司 | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease and its application |
Non-Patent Citations (7)
| Title |
|---|
| J N GEORGE: "Platelets", 《LANCET》 * |
| MILKA KOUPENOVA等: "Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis", 《CIRC RES》 * |
| 刘东方等: "中药抗血小板聚集的研究", 《湖北中医杂志》 * |
| 南京中医药大学编著: "5854 蟑螂", 《中药大辞典（第二版-下册）》 * |
| 唐晓鸿: "心脉隆注射液药理作用和治疗心力衰竭临床研究进展", 《中国新药杂志》 * |
| 李新成: "药名蟑螂之我见", 《西北药学杂志》 * |
| 王凤琴等: "血小板在活血化瘀中药研究中的应用", 《中国中药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109125355B (en) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Inagawa et al. | Ultrastructural alteration of pulmonary capillary endothelial glycocalyx during endotoxemia | |
| Qiu et al. | Pharmacological and clinical application of heparin progress: An essential drug for modern medicine | |
| Chen et al. | P2X7R/cryopyrin inflammasome axis inhibition reduces neuroinflammation after SAH | |
| Sullivan et al. | Altered skeletal muscle metabolic response to exercise in chronic heart failure. Relation to skeletal muscle aerobic enzyme activity. | |
| DE69130289T2 (en) | THERAPEUTIC USE OF ACTIN BINDING COMPOUNDS | |
| Holemans | Enhancement of fibrinolysis in the dog by injection of vasoactive drugs | |
| Hauser | Preclinical models of traumatic, hemorrhagic shock | |
| Harrison et al. | The variability of human platelet aggregation | |
| Fu et al. | Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5‐HT3 receptors | |
| Furman-Niedziejko et al. | Relationship between abdominal obesity, platelet blood count and mean platelet volume in patients with metabolic syndrome | |
| Li et al. | Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin | |
| Munsch et al. | Hydroxyethyl starch: an alternative to plasma for postoperative volume expansion after cardiac surgery | |
| US7384657B2 (en) | Composition of natural herb extract for treating cardiovascular disease and its method of preparation thereof | |
| Landsverk et al. | Impact of enzymatic degradation of the endothelial glycocalyx on vascular permeability in an awake hamster model | |
| Fearnley | Spontaneous fibrinolysis∗ | |
| Bacaksiz et al. | Does pantoprazole protect against reperfusion injury following myocardial ischemia in rats? | |
| CN106727625A (en) | Application of tannic acid in antithrombotic medicine | |
| Takemoto | Dose effects of propofol on hemodynamic and cytokine responses to endotoxemia in rats | |
| CN109125355A (en) | The grand antiplatelet of heart arteries and veins and antithrombotic pharmacology action | |
| Chen et al. | Effect of sildenafil on coronary active and reactive hyperemia | |
| Dennis et al. | Anticoagulant and antimalarial action of heparin in simian malaria | |
| CN111317736A (en) | Application of quinoline alkaloid in preparation of medicine for treating atherosclerosis | |
| Zampronio et al. | Indomethacin blocks the febrile response induced by interleukin-8 in rabbits | |
| Vardi et al. | Diffuse intravascular clotting associated with a primary brain tumour | |
| Niewiarowska et al. | Influence of dicoumarol derivatives on plasma fibrinolytic system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |